Post
of 161,349
Has to be true. The letter to shareholders said the the PREVIOUS study, without temozolomide, did not show a difference between the Leron and the control arm. And that was all we heard about it. So if they are posterizing it, the Leron plus temozolomide arm must have surpassed the control arm.
7